Adverse reactions occurring in ≥3% of patients receiving AKYNZEO and cisplatin-based chemotherapy regimens1
0.5 mg (n=136)
A single-cycle study of patients receiving cisplatin-based, highly emetogenic chemotherapy (AKYNZEO, n=136).1
Adverse reactions occurring in ≥3% of cancer patients receiving AKYNZEO and AC-based chemotherapy regimens1
0.5 mg (n=725)
A study of patients receiving AC-based chemotherapy treatment. 725 patients were treated with AKYNZEO during Cycle 1; 635 of these patients continued for up to 8 cycles in a multiple-cycle extension.